Formulation Innovations for ACTN4 Inhibition: Targeting Metastatic Pathways in Oral Cancer

Abstract

Oral cancer remains a major global health burden, with metastasis posing the most significant obstacle to curative management and survival improvement. ACTN4 (α-actinin-4), a cytoskeletal actin-binding protein, is overexpressed or amplified in aggressive oral squamous cell carcinomas and drives cytoskeletal remodeling, epithelial–mesenchymal transition, and metastatic invasion. Current chemotherapeutics poorly target ACTN4-mediated motility pathways and are limited by systemic toxicity and resistance. Emerging formulation innovations—such as nanoemulsions, liposomes, and herbal nanosystems—offer targeted delivery, enhanced intracellular uptake, and modulation of metastatic signaling. Liposomal and lipid-nanoparticle systems improve drug stability, circulation, and tumor selectivity, while herbal nanoformulations enable synergistic inhibition of ACTN4-linked oncogenic cascades. Artificial-intelligence-driven formulation design further enables predictive optimization of drug-excipient ratios, release kinetics, and targeting specificity. Integrating nanotechnology and AI presents a transformative avenue for next-generation ACTN4 inhibitors, paving the way toward precision therapeutics against metastatic oral cancer.